When the tables turn: Investigating the FDA

fda-blog-700

By Dr Nicola Davies

A key responsibility of the US Food and Drug Admi0nistration is holding pharma companies and other healthcare stakeholders accountable for the safety and efficacy of medicinal products. However, as the furor over the FDA’s approval of Biogen’s aducanumab (Aduhelm) rages on, we are forced to contemplate the accountability of the agency itself. We discuss other instances, from the last three years, in which the FDA was investigated.

Foreign drug inspections

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical